Category: Latest News
-
Oil holds above $110 as Middle East conflict fuels sharp March rally
Oil prices remained above $110 per barrel on Tuesday as markets balanced news of a tanker fire near Dubai with reports that U.S. President Donald Trump may be considering ending military operations against Iran. By 04:49 ET (08:49 GMT), Brent crude futures for May delivery, the global benchmark, were up 0.1% at $112.87 per barrel,…
-
Gold edges higher as markets watch Iran de-escalation; metal still heading for steep March losses
Gold prices climbed during Asian trading on Tuesday, recovering slightly after suffering heavy declines throughout March as rising inflation expectations tied to the U.S.–Israel conflict with Iran weighed on non-yielding assets such as precious metals. Sentiment in metals markets improved after reports indicated that U.S. President Donald Trump is weighing the possibility of scaling back…
-
Futures rise while oil stays elevated amid Iran conflict — key market drivers: Dow Jones, S&P, Nasdaq, Wall Street
U.S. equity futures moved higher on Tuesday as investors looked ahead to the final trading day of the first quarter, supported by reports that U.S. President Donald Trump may be considering ending the military campaign in Iran even if the Strait of Hormuz remains closed. Energy markets, however, stayed under pressure after a Kuwaiti oil…
-
Sekur Crosses Most Important Milestone in its History
Fortress Grade Security Is the Handwriting on the Wall? Reading the “Handwriting on the Wall” (HOW) is one of the more interesting Wall Street sayings we often hear, as it relates to small-cap companies. This week’s GSA announcement marks Sekur’s 4th major milestone. It was written on their wall, for everyone to review. Note this…
-
Mobix Labs (MOBX): Doubling Down on the “Drone Wars” Economy
For retail investors following the defense tech space, March 2026 is shaping up to be a pivotal month for Mobix Labs (NASDAQ:MOBX). The company just dropped two major updates that signal a strategic shift from being a “component supplier” to becoming a “systems intelligence” player. This article is disseminated in partnership with Mobix Labs Inc. It…
-
Oil Shock and Tech Weakness Push S&P 500 to Third Straight Loss
U.S. stocks finished Monday’s session mixed as surging oil prices and persistent weakness in the technology sector overshadowed tentative hopes for diplomatic progress in the Iran conflict. Brent crude shattered the $107 threshold during the session, ultimately settling near $113 a barrel as the Strait of Hormuz—responsible for roughly 21 million barrels per day of…
-
Kezar Life Sciences shares surge after Aurinia announces acquisition
Kezar Life Sciences Inc. (NASDAQ:KZR) shares jumped about 19% on Monday after Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced an agreement to acquire the company for $6.955 per share in cash plus a contingent value right (CVR). Under the terms of the deal, the CVR could provide additional payments tied to the clinical development or potential sale…
-
MakeMyTrip shares slide after short-seller report raises allegations
MakeMyTrip Limited (NASDAQ:MMYT) shares declined about 3.5% on Monday after Morpheus Research released a short-seller report alleging anti-competitive behavior and accounting concerns at the Indian online travel company. The report claims MakeMyTrip continues to apply price parity practices with hotel partners despite a 2022 ruling by India’s Competition Commission of India (CCI) ordering the company…
-
Nexstar shares drop after judge orders pause in Tegna merger
Shares of Nexstar Media Group (NASDAQ:NXST) fell about 9% on Monday after a federal judge ordered the broadcaster to halt further integration efforts tied to its recently completed merger with Tegna Inc. U.S. District Judge Troy L. Nunley in Sacramento granted a request from DirecTV to temporarily stop the deal while litigation over the merger…
-
Insmed shares rise after UTHR trial data and Morgan Stanley upgrade
Insmed (NASDAQ:INSM) shares climbed about 4.7% on Monday after analysts reacted to positive clinical data from United Therapeutics and Morgan Stanley upgraded the stock to Overweight from Equalweight. Morgan Stanley also raised its price target on Insmed to $212 from $166 after conducting proprietary survey research on the launch of Brinsupri for bronchiectasis. The firm’s…